It has been known that dementia can effect our sense of smell and that a biomarker of the smell of leather has been around for quite some time. The new study evidence from University of Colorado Anschutz Medical Campus points to a more generalized statement regarding COVID 19 causing olfactory inflammation. I believe we can use olfactory ERP measures to evaluate the severity of inflammation and then determine the efficacy of intranasal tPBM therapy using the same measures.
Quietmind is developing pilot trials using intranasal 1070nm stimulation, contact firstname.lastname@example.org with questions on enrollment.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.